IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION DOCKET NO.: 3211.1004-021

Applic	ant:	Keizo Koya, Lijun Sun, Mitsunori Ono, Weiwen Ying and Hao Li	i		
Contin	uation App	plication of			
	Applicatio	on No.: 10/244,088			
	Filed:	September 13, 2002			
Title:		1-GLYOXYLAMIDE INDOLIZINES FOR TREATING CANCER			
		Date: 5.20.04			
		EXPRESS MAIL LABEL NO. EU 05 Z 028 344 以	·		
		INFORMATION DISCLOSURE STATEMENT			
Commi	top Amendm issioner for I ox 1450 Idria, VA 22	Patents			
Sir:					
This Ir	under 37 (Disclosure Statement is submitted: CFR 1.129(a), or submission after Final Rejection)			
[X]	under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including CPA, or a Request for Continued Examination).				
[]	under 37 (CFR 1.97(c) together with either:			
	[] a S	Statement under 37 CFR 1.97(e), as checked below, or			
		\$180.00 fee under 37 CFR 1.17(p), or CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)			
[] under 37 CFR 1.97(d) together with:		CFR 1.97(d) together with:			
	[] a S	Statement under 37 CFR 1.97(e), as checked below, and			
		\$180.00 fee under 37 CFR 1.17(p), or al action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)			
[]	Applicant	CFR 1.97(i): t requests that the IDS and cited reference(s) be placed in the application filew rement of issue fee)	таррег.		

Statem	ent Unc	<u>ler 37 (</u>	<u>CFR 1.97(e)</u>		
[]	Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or				
[]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.				
Statem	ent Unc	<u>der 37 C</u>	(Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000		
[]	commitwee no	unicatio ot receiv	information contained in the Information Disclosure Statement was cited in a in from a foreign patent office in a counterpart application and this communication ared by any individual designated in § 1.56(c) more than thirty days prior to the aformation Disclosure Statement.		
[X]	Enclosed herewith is form PTO-1449:				
	[X]	Copies	s of the cited references are enclosed.		
		[X]	Since this application was filed after June 30, 2003, copies of issued U.S. patents and published U.S. applications are not required and are not being provided.		
	[X]	Applic	s of the cited references are enclosed except those entered in prior application, U.S. eation No. 10/244,088, to which priority under 35 U.S.C. 120 is claimed. [The application contains copies of the cited references.]		
	[]	The list	sted references were cited in the enclosed International Search Report in a expart foreign application.		
	[]		oncise explanation" requirement (non-English references) for reference(s) [37 CFR 1.98(a)(3) is satisfied by:		
		[]	the explanation provided on the attached sheet.		
		[]	the explanation provided in the Specification.		
		[]	submission of the enclosed International Search Report.		
		[]	submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.		
		ſΊ	the enclosed English language abstract.		

[X]	Applic	cant requests that the following no	on-published pending applic	eations be considered:
Examiner's Initials				
		U.S. Patent Application No. 10/ Hao Li, Shoujun Chen, Masazur No.: 3211.1012-000	319,401, by Mitsunori Ono, mi Nagai, Rongzhen Lu, file	Lijun Sun, Zhi-Qiang Xia, ed December 12, 2002, Docket
		U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
		U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
		Examiner	Date	_
	[X]	A copy of each above-cited app	lication, including the curre	nt claims, is enclosed.
	[]	A copy of each above-cited app those entered in prior application 35 U.S.C. 120 is claimed.	lication, including the curre on, U.S. Application No. [nt claims, is enclosed, except], to which priority under
The Ex	xamine nces we	r is requested to return a copy of reconsidered with the next office	the above list of pending ap	plications indicating which
It is re	quested	I that the information disclosed he	erein be made of record in the	his application.
Metho	d of pa	yment:		
[]	A cheaccom	ck for the fee noted above is encl panying Reply. A copy of this S	osed, or the fee has been inc tatement is enclosed.	cluded in the check with the
[]	Please	e charge Deposit Account 08-038 sed.	0 in the amount of \$[. A copy of this Statement is
[X]	Please	e charge any deficiency in fees an	d credit any overpayment to	Deposit Account 08-0380.
		R	Respectfully submitted,	
		H	IAMILTON, BROOK, SMI	TH & REYNOLDS, P.C.
		E	Steven G. Davis, Esq. Registration No.: 39,652 Telephone: (978) 341-0036 Facsimile: (978) 341-0136	5

Concord, MA 01742-9133 Dated: May 19 2004

PTO-1449 REPRODUCED 3			TINUATION OF /244,088	NUATION OF APPLICATION NO.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR FILING Keizo Koya		FILING DATE	NG DATE	
May 19, 2004 (Use several sheets if necessary)	EXAMINER	CONF	IRMATION NO.	GROUP	

		U.S	S. PATENT DOCUMENTS			
EXAM- INER INI- TIAL	REF. DOCUMENT NUMBER NO. Number-Kind Code (if known)		ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT		
	AA	6,214,855 B1	04-10-01	Gemba et al.		
	AB	6,461,538	10-08-02	Taguchi		
	AC	6,207,675	03-27-01	Carry et al.		
	AD	US 2003/0153759 A1	08-14-2003	Koya et al.		
	AE	US 2003/0204090	10-30-03	Ono et al.		
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AA2					
	AB2					
	AC2					
	AD2					
	AE2					
	AF2					
	AG2					
	AH2					
	Al2					
	AJ2					
	AK2					
	AA3					
	AB3					
	AC3					

EXAMINER	DATE CONSIDERED
	_

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. CONTINUATION OF APPLICA 10/244,088			APPLICATION NO.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION .	FIRST NAMED INVENTOR FILING DATE Keizo Koya		FILING DATE	
May 19, 2004	EXAMINER	CONFI	RMATION NO.	GROUP
(Use several sheets if necessary)				

	J	OREIGN PATENT DO	OCUMENTS		
	DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
AL	GB2287706A	09-27-1995	Fujisawa Pharmaceutical Co.		
AM	WO 99/59999	11-25-1999	Shionogi & Co., LTD		
AN	WO 00/21563	04-20-2000	Shionogi & Co., LTD		
AO	EP1085021A1	03-21-2001	Shionogi & Co., LTD		
AP	EP 1157704A1	11-28-2001	Shionogi & Co., LTD		
AQ	WO 9603383 A1	02-08-1996	Eli Lilly and Company		
AL2					
AM2					
AN2					
AO2					
AP2					
AQ2					
AL3					
AM3					
AN3					
AO3				_	
AP3					
AQ3					
AL4					
AM4					
AN4					
AO4					
AP4					
AQ4					

EXAMINER	DATE CONSIDERED